Management of kidney cancer: Canadian Kidney Cancer Forum Consensus Statement

Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021

“…For more than a decade, targeted systemic therapies have been the standard of care for metastatic renal cell carcinoma (mRCC) and their use has been refined over time as clinical experience has evolved. [1][2][3][4][5][6] The 2019 consensus statement by the Kidney Cancer Research Network of Canada (KCRNC) introduced the role of immunotherapy as first-line systemic therapy for mRCC, either as doublet immunotherapy or in combination with a vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), based on phase 3 studies that demonstrated improved survival compared to single-agent VEGFR-TKI (sunitinib). [7][8][9] Subsequently, there have been updates on two of the important previously report-ed phase 3 studies (CheckMate 214 and Keynote-426) that have reinforced prior results.…”

Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019

“…For more than a decade, targeted systemic therapies have been the standard of care for metastatic RCC (mRCC) and their use was refined over time as clinical experience evolved. [3][4][5][6][7][8] Since the last updated consensus statement by the Kidney Cancer Research Network of Canada (KCRNC) in 2017, the treatment landscape has shifted considerably and requires update.…”

Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update

“…T his is the most recent report from the Kidney Cancer Research Network of Canada (KCRNC), with an update from the 6th Canadian Kidney Cancer Forum held in February 2015 in Toronto, Ontario. [1][2][3][4] Kidney cancer, predominantly renal cell carcinoma (RCC), is the most lethal genitourinary malignancy and kills more than 1750 Canadians a year. 5 The overall incidence is increasing by 2% per year for unknown reasons, with most new cases being small renal masses.…”

“…There are several guidelines in Canada that address various aspects of RCC patient care. [1][2][3][4]6,7 Five previous forums were held in 2008, 2009, 2011, 2013, and 2014. As before, the 2015 meeting was small, by invitation and attended by survivors, caregivers, expert clinicians and researchers in fields relevant to kidney cancer care.…”